רווח לפני ריבית, מסים ופחת: citiuspharma.com (CTXR)

EBITDA reflects Citius Pharmaceuticals' preparation for the independent market launch of its oncology drug via distribution networks. Simultaneously, the company is implementing protective mechanisms for catheters to minimize hospital-acquired infections. The 0.00 level is a current metric confirming its leadership status in the treatment of T-cell lymphomas, supported by Lymphir patents that create a robust barrier for competitors.

The fundamental attractiveness of the asset is determined by its ability to generate a sustainable cash flow, making the analysis of operational efficiency key to calculating valuation multiples. The EBITDA trend reflects the actual volume of earnings before interest, taxes, depreciation, and amortization, demonstrating the ability of Citius Pharmaceuticals (CTXR) to monetize innovative drugs through settlements with insurance companies and government healthcare systems.